Member Info for Hurst10

Nice buy prints post hours.

More M&A in the diagnostic sector:
Thermo Fisher close to acquire diagnostics firm Binding Site for $2.3B - Bloomberg
Avacta’s diagnostic division and acquisition growing in valuation

Avacta Group PLC Price Monitoring Extension Kicked in!
Now NY wakes up!

With strong US participation and conference / Science day / News flow coming up and being the hottest placing this year so far.
It would in my opinion be impossible to acquire any size amount Monday AM and market will have to price it accordingly , hence 130-5 for starters, BEGO bidding 150 by lunch time, NY AM!
Tempting to take profits or sell forward, but very foolish to do so.
Most of you most never saw stocks like Nokia, ARM holdings etc , but when you enter a market with no size offer being made, it is off course time also to buy the quoted funds holding Avacta!!!
Good luck everybody
Remember “Silence is golden” ie the company or Royal Marden has never come out and said “ it did not work”

125-30 opening

Check out the new US shareholder!
Ref Convertible issue

Buy what you can at the opening!
Let us see you Thursday next week!

London accounts buying Monday
Opening 124-8
Closing 135-40
Conference with Avacta and Roche sharing the panel discussing FAP/AVA6000

83,369 bought at 121.90 post hrs print.not a bad move today. Similar move on Monday and come Tuesday we will be testing 2022 new highs.
A decent Burgundy awaits, have a good week end everybody.

Quite right.

NY wants the London listed Avacta stock
The stock is behaving as it has done most afternoons, with the usual MM on the bid and facilitating size buyers. Very standard stuff. 60/ bought at 1.20 20 min ago.20 bid shortly
Next week could be dynamite and wanting and paying up for stock now in such a case, is very normal.
With US investors holding equity of size and with the convertible being issued, you can tell that US want this ridiculously undervalued groundbreaking Biotech stock.Current est. of what AVA6000/3396 etc would make the Affimer programme worth, makes Avacta a huge buy for US biotech funds.
Buy the U.K. stock and wait for the Nasdaq listing with a re rating of the year coming up.
The 95p placing certainly made Christmas arrive early this year.

Early start in NY and guess what!
When they read on their screens that a $44 bill AUM company like Susquehanna and with their background are involved with Avacta, they will step up the buying big time! As mentioned this morning, NY wants stock and any size will now shortly be 125 offered with follow up offer at 130.
We now have several triple A US funds involved and Avacta’s performance will feature in their monthly investor updates.
A mill traded by 12.00 and 125-30!
Watch out for nice buy prints popping up.

As mentioned,
Size buyer up early and paying above offer price.
We will be 1 mill printed shortly
Susquehanna will make headlines everywhere.
Once they are officially listed, off to the races.
They do their homework!

115 offered coming up, demand for stock in front of next week with potentially more news from the therapeutic division and the IPCO FAP summit, with Avacta,Roche etc attending and presenting.
Size buyer at current offer price not possible.
NY will join us early today!

Nice to see Avacta back on the RNS run, a good test,before the “ real “ RNS!!

Low volume so far, as no sellers around, NY want more stock, usual MM will move the price, MAV Golden cross moving north and revised SOP, a lively afternoon coming up.

Early kick off in NY
Holders of the convertible etc will be enjoying the ride into 120-5 today, however who would want to sell ? before next week, virtual IPCO conference, news flow, re rating etc
Our patience will be rewarded 10x
Next step, how do you value the Therapeutic business with a Nasdaq listing vs current IPO’s

Interesting that at the IPCO Theranostics FAP Summit Virtual event, Fiona McLaughlin CSO at the Non-Radioligand Therapeutics session will be joined by Christian Klein of Roche.Will be interesting.
Christian Klein, Distinguished Scientist, is Department Head Cancer Immunotherapy (CIT) Discovery 3, Head Oncology Programs & Site Head Roche Innovation Center Zurich (RICZ), Roche Pharma Research & Early Development. He specialized in the discovery, engineering, validation and preclinical development of therapeutic/bispecific antibodies for CIT.

Japan's Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY) is acquiring a 15% stake in Taysha Gene Therapies (NASDAQ:TSHA) for $50M to support the advancement of Taysha's gene therapy programs for Rett syndrome and giant axonal neuropathy (GAN).

Under the agreement, Astellas will invest $50M to acquire 15% of the outstanding common stock of Taysha and to receive an exclusive option to license two clinic

Nasdaq listing for the therapeutic side, AVA6000 news before hand. Stifel US taking over.
What you need is a Science date and we are off to the races.
Enjoy